



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 10, 2006

Signature:

Shari Jackson
(Shari Jackson)

Docket No.: AREX-P03-005
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Madiyalakan et al.

Application No.: 10/824,554

Confirmation No.: 6247

Filed: April 14, 2004

Art Unit: 1641

For: METHOD FOR DIAGNOSING EFFICACY
OF XENOTYPIC ANTIBODY THERAPY

Examiner: Not Yet Assigned

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. A copy of reference C11 is enclosed herewith. Copies of the other cited references are not provided since copies of these references were provided in connection with U.S. Application No. 09/376,604 (our docket no. AREX-P03-004) and/or U.S. Application No. 09/152,698 (our docket no. AREX-P02-004). The

undersigned kindly requests that the Examiner consider the copies of the references provided in connection with those applications.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. AREX-P03-005. A duplicate copy of this paper is enclosed.

Dated: April 10, 2006

Respectfully submitted,

By 

Gloria Fuentes

Registration No.: 47,580

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



sPTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/824,554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	AREX-P03-005

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-4,740,371	04-26-1988	St. Remy et al.	
	AB	US-4,879,225	11-07-1989	Morgan Jr. et al.	
	AC	US-5,512,283	04-30-1996	Byers et al.	
	AD	US-5,532,159	07-02-1996	Webb et al.	
	AE	US-5,583,202	12-10-1996	Zanetti	
	AF	US-5,591,593	01-07-1997	Courtenay-Luck	
	AG	US-5,652,114	07-29-1997	Chu et al.	
	AH	US-5,688,657	11-18-1997	Tsang et al.	
	AI	US-5,725,856	03-10-1998	Hudziak et al.	
	AJ	US-5,869,445	02-09-1999	Cheever et al.	
	AK	US-5,997,315	11-02-1999	Chatterjee et al.	
	AL	US-6,068,830	05-30-2000	Diamandis et al.	
	AM	US-6,077,519	06-20-2000	Storkus et al.	
	AN	US-6,140,091	10-31-2000	Raso et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO 93/20185	10-14-1993	Steinman et al.		
	BB	WO 94/21287	09-29-1994	Berzofsky et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Algarra et al., "Altered MHC class I antigens in tumors", Int. J. of Clin. & Lab, 27:95-102 (1997).	
	CB	Antonia et al., "Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein", Int. Imm., 7:715-725 (1995).	
	CC	Bachmann et al., "Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen," Eur. J. Imm., 24:2567-70 (1994).	
	CD	Baum et al., "Activating Anti-Idiotypic Human Anti-Mouse Antibodies for Immunotherapy of Ovarian Carcinoma", Cancer, 73:1121-25 (1994).	
	CE	Benichou et al., "Disruption of the determinant hierarchy on a self-MHC peptide: concomitant tolerance induction to the dominant determinant and priming to the cryptic self-determinant", Int. Imm., 6:131-38 (1994).	
	CF	Bodey et al., "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy", Anticancer Res., 20:2665-2676 (2000).	
	CG	Chattopadhyay et al., "Human high molecular weight-melanoma associated antigen mimicry	

Examiner Signature	Date Considered
--------------------	-----------------

3190902

Substitute for form 1449A/B/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/824,554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	AREX-P03-005

		by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1," Cancer Res., 5:6045-51 (1991).	
	CH	Cibotti, PNAS, "Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants", 89:416-20 (1992).	
	CI	Clark, "Protein Engineering of antibody Molecules for Prophylactic and therapeutic Applications in Man, (monograph), Prot. Eng., 1 (1993).	
	CJ	Crowley et al., "Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins", J. Exp. Med., 172:383-386 (1990).	
	CK	De la Salle, "FcγR on Human Dendritic Cells", Human IgG Receptors, p. 39-55 (1996).	
	CL	Fagerberg, "Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A," Cancer Imm., 12:81-87 (1996).	
	CM	Frodin et al., Hybridoma, "Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?," 10:421-31 (1991).	
	CN	Goldenberg et al., "Cancer Diagnosis and Therapy with Radiolabeled Antibodies", In: Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer, Vogel. Ed., 259-280 (1987).	
	CO	Jurnic-Winkler, "Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen", Eur. Urol., 24:487-91 (1993).	
	CP	Keder et al., "Cancer Immunotherapy: Are the results discouraging? Can they be improved?," Adv. Cancer Res., 59:245-323 (1992).	
	CQ	Klaus, "Antigen-antibody complexes elicit anti-idiotypic antibodies to self-idiotopes," Nature, 272:265-66 (1978).	
	CR	Lee et al., "Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression", J. Imm., 163:6292-300 (1999).	
	CS	Leitzel, "Elevated Soluble c-erbB-2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients", J. Clin. Oncol., 10:1436-1442 (1992).	
	CT	McGuckin et al., "Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women," Clin. Chim. Acta, 214:139-51 (1993).	
	CU	Nishimura, "The critical role of TH1-dominant immunity in tumor immunology, Cancer Chemother", Cancer/Chemo, 46:S52-S61 (2000).	
	CV	Ohlen et al., "Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CB ^T Cells of CTL Immunotherapy of Tumors Expressing the Antigen", J. Imm., 166:2863-2870 (2001).	
	CW	Pani et al., "Failure of presented, nondominant self epitope to induce tolerance - implications for autoimmune-diseases", Imm. Inv., 23:337-346 (1994).	
	CX	Paul, "Factors limiting effective tumor immunity", Fund. Imm., 1163-69 (1993).	
	CY	Rooijen, "The role of the FDC-retained immune complex network and its dynamics in the activity of germinal centres," Res. Immunol., 144:545-52 (1993).	
	CZ	Sallusto, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α", J. Exp. Med., 179:1109-1118 (1994).	
	CA1	Schlom, In: Molecular foundations of Oncology, S. Broder, Ed., Mol. Fndns. Oncol., 105-107 (1991).	
	CB1	Schwartz, "Cancer Markers," In: Cancer: Principles and Practice of Clinical Oncology, 4 th Ed., 531-542 (1994).	
	CC1	Semino et al., "Heterogeneity of the alpha-interferon-mediated overexpression of class-I and class-II major histocompatibility complex molecules in primary cultured cancer cells", J. Biol. Regs., 7:99-105 (1993).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO				Complete If Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/824,554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	AREX-P03-005

	CD1	Tassi et al., "Immunogenicity of anti-idiotypic antibodies and of their F(ab') ₂ fragments," Imm. Letts., 27:39-44 (1991).	
	CE1	Vrba et al., "Carcinoembryonic antigen: evidence for multiple antigenic determinants and isoantigens", PNAS, 72:4602-06 (1975).	
	CF1	Ward, "Unconjugated antibodies for cancer therapy: lessons from the clinic" Cancer Treatment Rev., 23:305-319 (1997).	
	CG1	Watts et al., "Suppressive Effect of Antibody on Processing of T Cell Epitopes", J. Exp. Med., 178:1459-1463 (1993).	
	CH1	Yin et al., "Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer," Int. J. Cancer, 65-406-412 (1996).	
	CI1	Qi et al., "Induction of idiotype network to anti-MUC-1 antibody in breast cancer", Proceedings of the American Association for Cancer Research Annual, 39:367 (1998).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--